ADAPTOR PROTEIN Ruk/CIN85REGULATES REDOX BALANCE IN 4T1MOUSE BREAST CANCER CELLS EXPOSED TO PLASMIN(OGEN)
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17241Keywords:
adenocarcinoma 4T1 cells, breast cancer, glutathione-related enzyme system, plasminogen/plasmin, reactive oxygen species (ROS), Ruk/CIN85Abstract
Background: Cell surface plasmin is involved in tumor growth and metastatic dissemination by regulating cancer cells adhesion, migration and invasion. Plasmin-induced cell detachment is accompanied by an increased rate of reactive oxygen species (ROS) generation and cell death. However, cancer cells acquire the ability to develop adaptive mechanisms to resist ROS-mediated apoptosis. Aim: To establish the role of adaptor protein Ruk/CIN85 in the control of viability and redox balance in breast adenocarcinoma cells exposed to plasmin(ogen). Materials and Methods: Mouse 4T1 cells with the stable overexpression of adaptor protein Ruk/CIN85 (RukUp subline) and corresponding control (Mock subline) were treated with Glu-plasminogen (1–100 nM). Plasminogen to plasmin conversion was monitored spectrophotometrically by cleavage of the specific chromogenic substrate S2251. Specific uPA inhibitor BC11 was used to verify the uPA-mediated mechanism of plasminogen pericellular activation by 4T1 cells. Cell survival rate was assessed by MTT-test and cell proliferation was estimated by colony formation assay. Enzymatic activities of catalase, glutathione peroxidase, superoxide dismutase, as well as hydrogen peroxide (H2O2) levels were measured by spectrophotomertric and fluorometric assays. The intracellular ROS generation was monitored by flow cytometry using H2DCF-DA fluorescent probe. Results: Plasminogen was shown to be converted into an active proteinase plasmin on the surface of carcinoma cells in uPA-dependent manner. Plasmin(ogen) suppressed proliferation and affected survival of both studied 4T1 sublines. However, RukUp cells displayed higher resistance to plasmin(ogen)-induced cytotoxicity than Mock cells. Plasmin(ogen) promoted significant elevation in ROS generation rate in cells with the basal level of Ruk/CIN85 expression. In contrast, RukUp cells appear to be more effective in counteracting prooxidant changes due to the activation of some enzymes of the glutathione system, in particular glutathione peroxidase, and a concomitant decrease of H2O2 accumulation. Conclusion: Adaptor protein Ruk/CIN85 is involved in the regulation of redox homeostasis in cancer cells to maintain levels of ROS, thus promoting redox adaptation in cancer cells exposed to plasmin(ogen). Thus, Ruk/CIN85 may represent one of the relevant targets in order to diminish the resistance of cancer cells to ROS-mediated apoptosis.
References
Heissig B, Salama Y, Osada T, et al. The multifaceted role of plasminogen in cancer. Int J Mol Sci 2021; 22: 2304. https://doi.org/10.3390/ijms22052304
Stillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 2007; 9: R14. https://doi.org/10.1186/bcr1647
Doeuvre L, Plawinski L, Goux D, et al. Plasmin on adherent cells: from microvesiculation to apoptosis. Biochem J 2010; 432: 365–73. https://doi.org/10.1042/BJ20100561
Adeshakin FO, Adeshakin AO, Afolabi LO, et al. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol 2021; 11: 626577. https://doi.org/10.3389/fonc.2021.626577
Chio I, Tuveson DA. ROS in cancer: the burning question. Trends Mol Med 2017; 23: 411–29. https://doi.org/10.1016/j.molmed.2017.03.004
Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004; 2: 395–402.
Huang QT, Chen JH, Hang LL, et al. Activation of PAR-1/NADPH oxidase/ROS signaling pathways is crucial for the thrombin-induced sFlt-1 production in extravillous trophoblasts: possible involvement in the pathogenesis of preeclampsia. Cell Physiol Biochem 2015; 35: 1654–62. https://doi.org/10.1159/000373979
George S, Abrahamse H. Redox potential of antioxidants in cancer progression and prevention. Antioxidants (Basel) 2020; 9: 1156. https://doi.org/10.3390/antiox9111156
Lee KH, Kim JR. Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor. Exp Mol Med 2009; 41: 180–8. 10.3858/emm.2009.41.3.021
Havrylov S, Redowicz MJ, Buchman VL. Emerging roles of Ruk/CIN85 in vesicle-mediated transport, adhesion, migration and malignancy. Traffic 2010; 11: 721–31. https://doi.org/10.1111/j.1600-0854.2010.01061.x
Kozlova N, Mennerich D, Samoylenko A, et al. The pro-oncogenic adaptor CIN85 acts as an inhibitory binding partner of hypoxia-inducible factor prolyl hydroxylase 2. Cancer Res 2019; 79: 4042–56. https://doi.org/10.1158/0008-5472.CAN-18-3852
Samoylenko A, Vynnytska-Myronovska B, Byts N, et al. Increased levels of the HER1 adaptor protein Rukl/CIN85 contribute to breast cancer malignancy. Carcinogenesis 2012; 33: 1976–84. https://doi.org/10.1093/carcin/bgs228
Bazalii AV, Horak IR, Pasichnyk GV, et al. Transcriptional regulation of NOX genes express ion in human breast adenocarcinoma MCF-7 cells is modulated by adaptor protein Ruk/CIN85. Ukr Biochem J 2016; 88: 119–25. https://doi.org/10.15407/ubj88.01.119
Horak IR, Latyshko NV, Hudkova OO, et al. Adaptor protein Ruk/CIN85 affects redox balance in breast cancer cells. Ukr Biochem J 2020; 92: 24–34. https://doi.org/10.15407/ubj92.04.024
Horak IR, Pasichnyk GV, Gerashchenko DS, et al. Adaptor protein Ruk/CIN85 modulates manifestation of cancer stem cells (CSCs) features in mouse breast adenocarcinoma 4T1 cells. Rep Nat Acad Sci Ukr 2018; 12: 101–9.
Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255: 10214–22.
Horak IR, Gerashchenko DS, Drobot LB. Adaptor protein Ruk/CIN85 modulates chemoresistance to doxorubicin of murine 4T1 breast cancer cells. Ukr Biochem J 2018; 90: 94–100. https://doi.org/10.15407/ubj90.03.094
Gouri A, Dekaken A, El Bairi K, et al. Plasminogen activator system and breast cancer: potential role in therapy decision making and precision medicine. Biomark Insight 2016; 11: 105–11. https://doi.org/10.4137/BMI.S33372
Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol 2018; 8: 24. https://doi.org/10.3389/fonc.2018.00024
Kalyanaraman B, Darley-Usmar V, Davies KJ, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med 2012; 52: 1–6. https://doi.org/10.1016/j.freeradbiomed.2011.09.030
Reczek CR., Chandel NS. The two faces of reactive oxygen species in cancer. Ann Rev Cancer Biol 2017; 1: 79–98. https://doi.org/10.1146/annurev-cancerbio-041916-065808
Banfi C, Brioschi M, Barbieri SS, et al. Mitochondrial reactive oxygen species: a common pathway for PAR1- and PAR2-mediated tissue factor induction in human endothelial cells. J Thromb Haemost 2009; 7: 206–16. https://doi.org/10.1111/j.1538-7836.2008.03204.x
Hawk MA, Schafer ZT. Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem 2018; 293: 7531–7. https://doi.org/10.1074/jbc.TM117.000260
Tykhomyrov AA, Nedzvetsky VS, Aĝca CA, et al. Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells. Exp Oncol 2020; 42: 270–6. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-4.15253
Havrylov S, Ichioka F, Powell K, et al. Adaptor protein Ruk/CIN85 is associated with a subset of COPI-coated membranes of the Golgi complex. Traffic 2008; 9: 798–812. https://doi.org/10.1111/j.1600-0854.2008.00724.x
Nikolaienko OV, Skrypkina IYa, Tsyba LO, et al. ITSN1 and Ruk/CIN85 colocalized to clathrin coated pits in MCF-7 cells. Biopol Cell 2009; 25: 424–7.
Bazalii АV, Vorotnikov AV, Тyurin-Кuzmin PA, et al. Recombinant fluorescent sensor of hydrogen peroxide HyPer fused with adaptor protein Ruk/CIN85: designing of expression vector and functional characterization. Biotech Acta 2015; 8: 19–26.
Zhang J, Zheng X, Yang X, Liao K. CIN85 associates with endosomal membrane and binds phosphatidic acid. Cell Res 2009; 19: 733–46.
Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules 2020; 10: 1429. https://doi.org/10.3390/biom10101429
Dastmalchi N, Baradaran B, Latifi-Navid S, et al. Antioxidants with two faces toward cancer. Life Sci 2020; 258: 118186. https://doi.org/10.1016/j.lfs.2020.118186
Ko YH, Domingo-Vidal M, Roche M, et al. TP53-inducible glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancer. J Biol Chem 2016; 291: 26291–303. https://doi.org/10.1074/jbc.M116.740209
Fendt SM, Lunt SY. Dynamic ROS regulation by TIGAR: balancing anti-cancer and pro-metastasis effects. Cancer Cell 2020; 37: 141–2. https://doi.org/10.1016/j.ccell.2020.01.009
Shen M, Zhao X, Zhao L, et al. Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer. Mol Cancer 2018; 17: 88. https://doi.org/10.1186/s12943-018-0839-4
Agca CA, Kırıcı M, Nedzvetsky VS, et al. The effect of TIGAR knockdown on apoptotic and epithelial-mesenchymal markers expression in doxorubicin-resistant non-small cell lung cancer A549 cell lines. Chem Biodivers 2020; 17: e2000441. https://doi.org/10.1002/cbdv.202000441
Bazalii AV, Samoylenko AA, Petukhov DM, et al. Interaction between adaptor proteins Ruk/CIN85 and Tks4 in normal and tumor cells of different tissue origins. Biopol Cell 2014; 30: 37–41.
Samoylenko AA, Byts NV, Pasichnyk GV, et al. Recombinant lentivirus-mediated silencing of adaptor protein Ruk/CIN85 expression influences biological responses of tumor cells. Biotech Acta 2015; 8: 182–9.
Horak IR, Drobot LB, Borsig L, et al. Overexpression of adaptor protein Ruk/CIN85 in mouse breast adenocarcinoma 4T1 cells induces an increased migration rate and invasion potential. Biopol Cell 2018; 34: 284–91.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
